Back to top

gene-editing: Archive

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

VRTXPositive Net Change ANIPPositive Net Change FATEPositive Net Change EDITPositive Net Change

Zacks Equity Research

Agilent Expands LSAG Segment: How Should You Approach the Stock?

A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.

ITRIPositive Net Change APositive Net Change TERPositive Net Change FTVPositive Net Change

Ahan Chakraborty

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.

VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change

Zacks Equity Research

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

ALNYNegative Net Change CPRXPositive Net Change ANIPPositive Net Change RAREPositive Net Change